Arlington Capital Partners, a Washington, DC-based private equity firm, has acquired Micron Technologies in partnership with the company’s management team. Headquartered in Malvern, PA, Micron is a provider of particle size engineering and related analytical services. Terms of the acquisition were not disclosed. Greenberg Traurig served as counsel to Arlington for the transaction; Fairmount Partners advised Micron.
 
“Micron’s ability to provide leading bio-availability solutions across the drug development spectrum, from clinical phases to the commercial market, positions the company as a trusted long-term partner with its pharmaceutical clients for their most demanding drug development needs” said Matt Altman, a partner at Arlington Capital Partners. “We are enthusiastic about building upon the company’s leadership position and eager to continue to support the company as it enhances and expands its global particle size engineering and analytical service offerings.”
 
Joseph Drost, Micron’s chief executive officer, commented, “We are extremely excited about our partnership with Arlington Capital. Arlington has a successful history of investing in healthcare and pharmaceutical services and shares our vision for growing Micron’s global capabilities and service offerings. Arlington’s ability to provide significant strategic and capital support will further enable Micron to continue to expand our leading global position and better serve our worldwide pharmaceutical client base.”
 
David Wodlinger, a principal at Arlington Capital said, “Micron is an ideal platform investment in a compelling growth industry and we look forward to working closely with the company’s management team to expand the business aggressively, both organically and through acquisition.”